Pioneering precision medicine

AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases.

Since AC Immune’s foundation in 2003, our staff has developed pioneering scientific and clinical expertise in the understanding and treatment of neurodegeneration. Our deep knowledge and cutting-edge technology platforms, SupraAntigen® and Morphomer®, are the engines for our diverse pipeline of clinical and preclinical product candidates.

Our experienced management team combines outstanding scientific, clinical, regulatory, financial and corporate development competencies to build on the seminal work of AC Immune’s founders.

The Board of Directors includes leading industry veterans, who oversee and optimize our corporate strategy and execution. We also benefit from working closely with collaboration partners, investors, clinicians and academic researchers.

~150 Employees
CH / US based in Switzerland with a subsidiary in the US
2003 Founded in
2016 listed on NASDAQ

Our History

AC Immune’s “firsts” and partnerships highlight the excellence of our research, cutting-edge product candidates and the power of our technology platforms in the field of neurodegenerative diseases.

First positive cognitive results for an anti-Tau mAb therapy in Alzheimer’s


First clinically validated anti-a-syn vaccine acquired


First-in-human clinical study of latest diagnostic a-syn PET tracer


Anti-TDP-43 antibody shown to mitigate TDP-43 neuropathology in vivo


Morphomer® Tau small molecule aggregation inhibitor clinical trial (ACI-3024)


Lilly partnership on Morphomer® Tau aggregation inhibitors ($1.86 billion)


Clinical data for Tau PET tracer in progressive supranuclear palsy


Nasdaq IPO


Clinical vaccine trial in Down syndrome (Abeta vaccine)


Janssen partnership for Tau vaccine ($509 million)


Anti-phospho-Tau vaccine clinical trial in Alzheimer’s


Prevention trial in Alzheimer’s disease (crenezumab)


Start of clinical development of anti-Abeta vaccine ACI-24


Genentech partnership for anti-Tau antibody semorinemab ($418 million)


Genentech partnership for anti-Abeta antibody crenezumab ($300 million)


AC Immune founded in Lausanne, Switzerland


Our teams

Leadership, collaboration and experience accelerate success.

AC Immune Logo | Pioneering Precision Medicine for neurodegenerative diseases
AC Immune Partners | Pioneering Precision Medicine for neurodegenerative diseases


AC Immune’s scientific excellence has been validated through our collaborations with industry-leaders such as Genentech, Janssen, Life Molecular Imaging and Lilly.